JP2014505017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505017A5 JP2014505017A5 JP2013537218A JP2013537218A JP2014505017A5 JP 2014505017 A5 JP2014505017 A5 JP 2014505017A5 JP 2013537218 A JP2013537218 A JP 2013537218A JP 2013537218 A JP2013537218 A JP 2013537218A JP 2014505017 A5 JP2014505017 A5 JP 2014505017A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- compound
- pharmaceutical composition
- present
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- VOGXDRFFBBLZBT-AAQCHOMXSA-N 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(O)=O VOGXDRFFBBLZBT-AAQCHOMXSA-N 0.000 claims 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 3
- 102000018616 Apolipoproteins B Human genes 0.000 claims 2
- 108010027006 Apolipoproteins B Proteins 0.000 claims 2
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000003078 antioxidant Effects 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 239000001828 Gelatine Substances 0.000 claims 1
- 229960001295 Tocopherol Drugs 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 125000002640 tocopherol group Chemical group 0.000 claims 1
- 229930003799 tocopherols Natural products 0.000 claims 1
Claims (18)
- ApoB上昇、一次性高コレステロール血症(ヘテロ接合性家族性および非家族性)、一次性異常βリポタンパク血症(Fredrickson III型)から選択される少なくとも1つの疾患または状態を処置または予防するための医薬組成物の製造のための薬学的有効量の式(I)
の化合物の使用。 - 前記化合物がエナンチオマー、ジアステレオマーまたはこれらの混合物の形態で存在する、請求項1に記載の使用。
- R1およびR2が水素原子、メチル基、エチル基、n−プロピル基およびイソプロピル基から選択される、請求項1に記載の使用。
- 前記化合物がR体で存在する、請求項2に記載の使用。
- 前記化合物がS体で存在する、請求項2に記載の使用。
- 前記化合物がラセミ体で存在する、請求項2に記載の使用。
- R1が水素原子であり、R2がエチル基であり、前記式が
- 前記化合物が式
- 式(I)の前記化合物の薬学的有効量が、1用量当たり5mg〜3gの範囲にある、請求項1に記載の使用。
- 前記化合物が1日1回投与される、請求項1に記載の使用。
- 前記化合物が経口投与用の医薬組成物として製剤化される、請求項1に記載の使用。
- 前記医薬組成物がゼラチンカプセル剤または錠剤の形態である、請求項11に記載の使用。
- 前記医薬組成物が少なくとも1つの結合剤、添加剤、希釈剤またはこれらの任意の組み合わせをさらに含む、請求項12に記載の使用。
- 前記医薬組成物が抗酸化剤をさらに含む、請求項11に記載の使用。
- 前記抗酸化剤がトコフェロールまたはBHAである、請求項14に記載の使用。
- ApoB上昇、一次性高コレステロール血症(ヘテロ接合性家族性および非家族性)、一次性異常βリポタンパク血症(Fredrickson III型)から選択される少なくとも1つの疾患または状態を処置または予防するための医薬組成物の製造のための薬学的有効量の2−((5Z,8Z,11Z,14Z,17Z)−イコサ−5,8,11,14,17−ペンタエン−1−イルオキシ)ブタン酸
- 2−((5Z,8Z,11Z,14Z,17Z)−イコサ−5,8,11,14,17−ペンタエン−1−イルオキシ)ブタン酸の薬学的有効量が、1用量当たり5mg〜3gの範囲にある、請求項16に記載の使用。
- 2−((5Z,8Z,11Z,14Z,17Z)−イコサ−5,8,11,14,17−ペンタエン−1−イルオキシ)ブタン酸が1日1回投与される、請求項17に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41044510P | 2010-11-05 | 2010-11-05 | |
US61/410,445 | 2010-11-05 | ||
PCT/IB2011/002925 WO2012059818A1 (en) | 2010-11-05 | 2011-11-03 | Methods of treatment using lipid compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014505017A JP2014505017A (ja) | 2014-02-27 |
JP2014505017A5 true JP2014505017A5 (ja) | 2014-12-18 |
Family
ID=46024069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537218A Pending JP2014505017A (ja) | 2010-11-05 | 2011-11-03 | 脂質化合物を用いる処置方法 |
Country Status (21)
Country | Link |
---|---|
US (1) | US9394228B2 (ja) |
EP (1) | EP2635270B1 (ja) |
JP (1) | JP2014505017A (ja) |
KR (3) | KR102265409B1 (ja) |
CN (2) | CN103347508A (ja) |
AR (1) | AR083772A1 (ja) |
AU (1) | AU2011324909B2 (ja) |
BR (1) | BR112013010890B1 (ja) |
CA (1) | CA2816949C (ja) |
CO (1) | CO6771414A2 (ja) |
EA (1) | EA028535B1 (ja) |
ES (1) | ES2618604T3 (ja) |
IL (1) | IL226116B (ja) |
MX (1) | MX350720B (ja) |
MY (1) | MY170076A (ja) |
NZ (1) | NZ610705A (ja) |
SG (2) | SG190114A1 (ja) |
TW (2) | TWI578984B (ja) |
UA (1) | UA111475C2 (ja) |
WO (1) | WO2012059818A1 (ja) |
ZA (1) | ZA201303813B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009061208A1 (en) | 2007-11-09 | 2009-05-14 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
PT2427415T (pt) | 2009-05-08 | 2019-05-31 | Basf As | Ácidos gordos polinsaturados para o tratamento de doenças relacionadas com as áreas cardiovascular, metabólica e de doença inflamatória |
UA111475C2 (uk) | 2010-11-05 | 2016-05-10 | Пронова Байофарма Нордж Ас | Способи лікування із застосуванням ліпідних сполук |
PL2961727T3 (pl) * | 2013-02-28 | 2017-06-30 | Pronova Biopharma Norge As | Sposób wytwarzania kwasu 2-((5Z,8Z, 11Z,14Z,17Z)-ejkoza-5,8,11,14,17-pentaenyloksy)butanowego |
EP2961384B1 (en) | 2013-02-28 | 2019-08-28 | Basf As | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
JP7341916B2 (ja) * | 2015-04-01 | 2023-09-11 | ビーエーエスエフ エーエス | アポc3を低下させるためのチアオキソ化合物の使用 |
RU2705991C2 (ru) * | 2015-04-01 | 2019-11-13 | Пронова Биофарма Норге Ас | Применение тиаоксосоединений для уменьшения содержания аро с3 |
CA2983377C (en) | 2015-04-28 | 2023-08-29 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis |
WO2019111048A1 (en) | 2017-12-06 | 2019-06-13 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
JP2023554524A (ja) * | 2020-12-22 | 2023-12-27 | ノースシー セラピューティクス ベスローテン フェンノートシャップ | 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909554A (en) | 1956-07-23 | 1959-10-20 | Monsanto Chemicals | Process for the manufacture of (alkylmercapto) alkyl sulfates |
GB1038723A (ja) | 1962-03-26 | |||
JPS4839001B1 (ja) | 1970-11-09 | 1973-11-21 | ||
US4040781A (en) | 1974-06-06 | 1977-08-09 | Lever Brothers Company | Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same |
US4032564A (en) | 1974-09-09 | 1977-06-28 | Zoecon Corporation | Esters of cyclopropylalkanols |
GB1523276A (en) | 1974-09-20 | 1978-08-31 | Lafon Labor | Sulphur-containing amino compounds |
US4009211A (en) | 1975-07-29 | 1977-02-22 | Gulf Research & Development Company | Beta,beta-dialkylethylmercaptoethoxylate as new compounds |
US4209410A (en) | 1976-04-28 | 1980-06-24 | Phillips Petroleum Company | Lubricants |
EP0002007B1 (de) | 1977-11-11 | 1982-07-28 | Ciba-Geigy Ag | Neue Pyridindicarbonsäureesterderivate und ihre Gemische mit metallhaltigen Stabilisatoren sowie ihre Verwendung zur Stabilisierung von chlorhaltigen Thermoplasten |
JPS5570841A (en) | 1978-11-24 | 1980-05-28 | Konishiroku Photo Ind Co Ltd | Forming method of dye image |
US4368190A (en) | 1980-04-17 | 1983-01-11 | Merck & Co., Inc. | Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation |
EP0050327B1 (de) | 1980-10-21 | 1984-06-20 | Roche Diagnostics GmbH | Neue schwefelhaltige Phospholipide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US4411808A (en) | 1982-08-04 | 1983-10-25 | Exxon Research & Engineering Co. | Multifunctional additive for power transmission shift fluids |
US4775223A (en) | 1984-09-20 | 1988-10-04 | Canon Kabushiki Kaisha | Lactic acid derivative, liquid crystal composition containing same and liquid crystal device |
CA2010000A1 (en) | 1989-04-07 | 1990-10-07 | Paul B. Merkel | Photographic recording material containing a cyan dye-forming coupler |
JPH0451149A (ja) | 1990-06-19 | 1992-02-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
FR2663928B1 (fr) | 1990-06-27 | 1994-04-08 | Norsolor | Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres. |
EP0487809A1 (en) | 1990-11-28 | 1992-06-03 | Monsanto Europe S.A./N.V. | Rubber compositions having improved processability and improved rubber-vulcanisate properties |
JPH0543529A (ja) | 1991-08-10 | 1993-02-23 | Taisho Pharmaceut Co Ltd | アルカンアミドアンモニウム化合物 |
JP2793458B2 (ja) | 1992-03-19 | 1998-09-03 | 三井化学株式会社 | コネクター用ポリアミド系樹脂組成物およびコネクター |
JP2755279B2 (ja) | 1992-03-19 | 1998-05-20 | 三井化学株式会社 | 熱可塑性樹脂組成物およびその成形体 |
CA2164717C (en) | 1993-06-10 | 2009-10-20 | Louis S. Kucera | Method of combatting hepatitis b virus infection |
JP3110918B2 (ja) | 1993-06-18 | 2000-11-20 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
US5523430A (en) | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
DK70295A (da) | 1994-07-01 | 1996-01-02 | Ciba Geigy Ag | Titan- og zirkonium-komplekser af carboxylsyrer som korrosionsinhibitorer |
KR100463709B1 (ko) | 1994-10-13 | 2005-08-04 | 위민스 앤드 칠드런스 호스피털 애드레이드 | 변형된불포화지방산 |
US7517858B1 (en) | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
FR2741619B1 (fr) | 1995-11-28 | 1998-02-13 | Pf Medicament | Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique |
GB2328155B (en) | 1996-04-12 | 2000-08-02 | Peptide Technology Pty Limited | Methods of treating immunopathologies using polyunsaturated fattyacids |
EP1019059A4 (en) | 1997-01-24 | 2004-01-14 | Univ California | USE OF FXR, PPAR-ALPHA AND LXR-ALPHA ACTIVATORS TO RESTORE THE BARRIER FUNCTION, TO PROMOTE EPIDERMIS DIFFERENTIATION, AND TO PROLIFERATE |
US6060515A (en) | 1997-01-24 | 2000-05-09 | The Regents Of The University Of California | Treatment of skin conditions by use of PPARα activators |
JPH11180929A (ja) | 1997-12-19 | 1999-07-06 | Asahi Glass Co Ltd | エステル誘導体 |
WO1999058120A1 (en) | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
FR2786187B1 (fr) | 1998-11-19 | 2001-11-09 | Univ Paris Curie | Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations |
FR2792312B1 (fr) | 1999-04-15 | 2001-06-08 | Oreal | Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation |
US6723717B1 (en) | 1999-06-01 | 2004-04-20 | The University Of Texas Southwestern Medical Center | Sulfur-containing thyroxane derivatives and their use as hair growth promotors |
AR018472A1 (es) | 1999-06-01 | 2001-11-14 | Procter & Gamble | Compuesto, composicion y metodo para el tratamiento de la perdida de cabello |
NO328803B1 (no) | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
FR2828487B1 (fr) | 2001-08-09 | 2005-05-27 | Genfit S A | Nouveaux composes derives d'acides gras, preparation et utilisations |
US20030147814A1 (en) | 2001-12-21 | 2003-08-07 | 3M Innovative Properties Company | Medicinal aerosol formulations comprising ion pair complexes |
GB2383355A (en) | 2001-12-22 | 2003-06-25 | Schlumberger Holdings | An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant |
GB0202002D0 (en) | 2002-01-29 | 2002-03-13 | Leiv Eiriksson Nyotek A S | Use |
BR0307265B1 (pt) | 2002-01-31 | 2012-11-27 | composição substancialmente isenta de solvente, emulsão concentrada, e processo para tratamento e conferência de repelência à água a materiais fibrosos, couro, peles e têxteis. | |
AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
FR2845991B1 (fr) | 2002-10-16 | 2005-02-04 | Pf Medicament | Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine |
US8372430B2 (en) | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
WO2004076404A1 (ja) | 2003-02-28 | 2004-09-10 | Kaneka Corpration | 2位に置換基を有する光学活性化合物の製造法 |
DE10326303A1 (de) | 2003-06-11 | 2004-12-30 | Celares Gmbh | Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung |
JP2007522118A (ja) | 2004-01-30 | 2007-08-09 | ペプリン バイオリピッズ ピーティーワイ エルティーディー | 治療用分子および担体分子 |
JP4563114B2 (ja) | 2004-08-30 | 2010-10-13 | 出光興産株式会社 | 潤滑剤用添加剤 |
CA2599673A1 (en) | 2005-03-08 | 2006-09-14 | Reinhold Oehrlein | Metal oxide nanoparticles coated with specific n-acylaminomethylene phosphonates |
CN101213281B (zh) | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
WO2006117668A1 (en) | 2005-05-04 | 2006-11-09 | Pronova Biopharma Norge As | Fatty acid analogues, i.e. dha derivatives for uses as a medicament |
US20070167529A1 (en) | 2006-01-17 | 2007-07-19 | Walton Rebecca A | Antimicrobial compositions for treating fabrics and surfaces |
ES2391305T3 (es) | 2006-04-12 | 2012-11-23 | Unilever N.V. | Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel |
EP1849449A1 (en) | 2006-04-26 | 2007-10-31 | 3M Innovative Properties Company | Filler containing composition and process for production and use thereof |
US7763607B2 (en) | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
BRPI0713096A2 (pt) | 2006-05-09 | 2012-10-16 | Hemaquest Pharmaceuticals Inc | métodos para tratar distúrbios sangüìneos |
US20100240616A1 (en) | 2006-11-01 | 2010-09-23 | Anne Kristin Holmeide | Novel lipid compounds |
KR101438177B1 (ko) | 2006-11-01 | 2014-09-05 | 프로노바 바이오파마 너지 에이에스 | 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질 |
WO2008053340A1 (en) | 2006-11-03 | 2008-05-08 | Pronova Biopharma Norge As | A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent |
CN101225064A (zh) | 2007-01-19 | 2008-07-23 | 上海汇瑞生物科技有限公司 | 一种制备β-硫杂-α-烷基脂肪酸的新方法 |
DE102007017179A1 (de) | 2007-04-12 | 2008-10-23 | Clariant International Ltd. | Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation |
JP5575651B2 (ja) | 2007-10-31 | 2014-08-20 | プロノヴァ バイオファーマ ノルゲ アーエス | 新規のdha誘導体およびその医薬品としての用途 |
WO2009061208A1 (en) * | 2007-11-09 | 2009-05-14 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
CN101259118B (zh) * | 2008-01-31 | 2010-06-16 | 中国科学院广州生物医药与健康研究院 | 2’,4’-二羟基-6’-甲氧基-3’,5’-二甲基查耳酮作为PPARγ激动剂的应用 |
WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
FR2933006B1 (fr) | 2008-06-27 | 2010-08-20 | Inst Francais Du Petrole | Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante |
EP2813486B1 (en) | 2008-07-08 | 2017-10-25 | Catabasis Pharmaceuticals, Inc. | Fatty acid acetylated salicylates and their uses |
EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
PH12019500030A1 (en) * | 2009-03-09 | 2020-02-10 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
EP2248798A1 (en) | 2009-05-08 | 2010-11-10 | Pronova BioPharma Norge AS | Novel lipid compounds |
PT2427415T (pt) * | 2009-05-08 | 2019-05-31 | Basf As | Ácidos gordos polinsaturados para o tratamento de doenças relacionadas com as áreas cardiovascular, metabólica e de doença inflamatória |
DK2473045T3 (en) | 2009-09-01 | 2016-12-12 | Catabasis Pharmaceuticals Inc | Niacin-FATTY ACID CONJUGATES AND THEIR USES |
TW201138832A (en) | 2010-01-20 | 2011-11-16 | Pronova Biopharma Norge As | Salicylate fatty acid derivatives |
UA111475C2 (uk) | 2010-11-05 | 2016-05-10 | Пронова Байофарма Нордж Ас | Способи лікування із застосуванням ліпідних сполук |
WO2012115695A1 (en) | 2011-02-25 | 2012-08-30 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
WO2013016531A2 (en) | 2011-07-26 | 2013-01-31 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
-
2011
- 2011-11-03 UA UAA201305822A patent/UA111475C2/uk unknown
- 2011-11-03 KR KR1020197016734A patent/KR102265409B1/ko active IP Right Grant
- 2011-11-03 MX MX2013005022A patent/MX350720B/es active IP Right Grant
- 2011-11-03 KR KR1020137014384A patent/KR20130132836A/ko active Search and Examination
- 2011-11-03 CN CN2011800640854A patent/CN103347508A/zh active Pending
- 2011-11-03 AU AU2011324909A patent/AU2011324909B2/en active Active
- 2011-11-03 US US13/883,405 patent/US9394228B2/en active Active
- 2011-11-03 WO PCT/IB2011/002925 patent/WO2012059818A1/en active Application Filing
- 2011-11-03 KR KR1020207008118A patent/KR20200034814A/ko not_active Application Discontinuation
- 2011-11-03 SG SG2013033832A patent/SG190114A1/en unknown
- 2011-11-03 CA CA2816949A patent/CA2816949C/en active Active
- 2011-11-03 SG SG10201509127YA patent/SG10201509127YA/en unknown
- 2011-11-03 BR BR112013010890-8A patent/BR112013010890B1/pt active IP Right Grant
- 2011-11-03 JP JP2013537218A patent/JP2014505017A/ja active Pending
- 2011-11-03 EA EA201390659A patent/EA028535B1/ru not_active IP Right Cessation
- 2011-11-03 ES ES11837647.4T patent/ES2618604T3/es active Active
- 2011-11-03 CN CN201710806301.7A patent/CN107496395A/zh active Pending
- 2011-11-03 MY MYPI2013001591A patent/MY170076A/en unknown
- 2011-11-03 NZ NZ610705A patent/NZ610705A/en unknown
- 2011-11-03 EP EP11837647.4A patent/EP2635270B1/en active Active
- 2011-11-04 AR ARP110104131A patent/AR083772A1/es unknown
- 2011-11-04 TW TW100140360A patent/TWI578984B/zh active
- 2011-11-04 TW TW105133054A patent/TW201701875A/zh unknown
-
2013
- 2013-05-02 IL IL226116A patent/IL226116B/en active IP Right Grant
- 2013-05-24 ZA ZA2013/03813A patent/ZA201303813B/en unknown
- 2013-06-05 CO CO13136481A patent/CO6771414A2/es not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014505017A5 (ja) | ||
JP2010077141A5 (ja) | ||
JP2014500861A5 (ja) | ||
JP2012526094A5 (ja) | ||
JP2013545785A5 (ja) | ||
JP2013519632A5 (ja) | ||
JP2009530398A5 (ja) | ||
JP2010265321A5 (ja) | ||
JP2015505296A5 (ja) | ||
ES2759312T3 (es) | Compuestos de aminocarbonilcarbamato | |
JP2016512531A5 (ja) | ||
JP2012506896A5 (ja) | ||
JP2015537020A5 (ja) | ||
JP2009504763A5 (ja) | ||
NZ702826A (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
JP2012532883A5 (ja) | ||
JP2020097577A5 (ja) | ||
WO2009095872A3 (en) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors | |
NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
JP2013522368A5 (ja) | ||
JP2018515463A5 (ja) | ||
JP2008542386A5 (ja) | ||
JP2013513607A5 (ja) | ||
JP2005536503A5 (ja) | ||
JP2009040767A5 (ja) |